C=C1CCN(c2ccc(C(F)(F)F)cc2)C1=O
The rationale for this design is based on the importance of the gamma-lactam interaction with the Mpro seen by numerous reversible covalent inhibitors, including Pfizer's oral antiviral entering Phase 1 clinical trials.